MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1
Oncogene2016Vol. 35(48), pp. 6189–6202
Citations Over TimeTop 10% of 2016 papers
Leandro Venturutti, Rosalía I. Cordo Russo, Martín A. Rivas, María F. Mercogliano, Franco Izzo, Robert H. Oakley, Matías G. Pereyra, Mara De Martino, Cecilia J. Proietti, Patricio Yankilevich, Juan Carlos Roa, Pablo Guzmán, E Cortese, Daniel H. Allemand, Tzu-Hsuan Huang, Eduardo H. Charreau, John A. Cidlowski, Roxana Schillaci, Patricia V. Elizalde
Related Papers
- → A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study(2019)10 cited
- → Lapatinib: A competitor or companion to trastuzumab?(2009)8 cited
- Effects of trastuzumab and lapatinib on HER2 positive breast cancer treatment.(2019)
- → Abstract 613: Increased PI3K/AKT activity, which confers resistance to trastuzumab, can be overcome by lapatinib(2010)
- → Lapatinib Plus Trastuzumab Was Not Superior to Trastuzumab Alone or Trastuzumab Followed by Lapatinib for Improved DFS in Women with HER2+ Breast Cancer(2014)